Product Information

CAS No.	380449-51-4
Product Name	Melphalan Flufenamide

Associated Conditions

neoplasm·AL amyloidosis·multiple myeloma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.

HemaSphere • Vol. 5, Issue 7 • 2021

PMID: 34136753 PMC: PMC8202573 DOI: 10.1097/HS9.0000000000000602

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 39, Issue 7 • 2021

PMID: 33296242 PMC: PMC8078327 DOI: 10.1200/JCO.20.02259

Melphalan Flufenamide (Melflufen): First Approval.

Drugs • Vol. 81, Issue 8 • 2021

PMID: 33961277 DOI: 10.1007/s40265-021-01522-0

Melflufen for relapsed and refractory multiple myeloma.

Expert opinion on investigational drugs • Vol. 29, Issue 10 • 2020

PMID: 32924646 DOI: 10.1080/13543784.2020.1808884

Melphalan Flufenamide

CAS No.	380449-51-4
MDL No.	N/A
MF	C₂₄H₃₀Cl₂FN₃O₃
MW	498.40
InChI Key	YQZNKYXGZSVEHI-VXKWHMMOSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	380449-51-4
Product Name	Melphalan Flufenamide

Associated Conditions

neoplasm·AL amyloidosis·multiple myeloma

* The information provided here is compiled from public sources and is for reference only.

Melphalan Flufenamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Melphalan Flufenamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

Melphalan Flufenamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Melphalan Flufenamide (Melflufen): First Approval.

Melflufen for relapsed and refractory multiple myeloma.

Similar Products

Melphalan Flufenamide Hydrochloride

Melphalan Flufenamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Melphalan Flufenamide (Melflufen): First Approval.

Melflufen for relapsed and refractory multiple myeloma.

Similar Products

Melphalan Flufenamide Hydrochloride

Documentation